Valsartan for the treatment of heart failure

Author： Latini Roberto   Masson Serge   Staszewsky Lidia   Maggioni Aldo P  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.1, 2004-01, pp. : 181-193

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Valsartan: In Chronic Heart Failure

By Wellington K.   Goa K.L.  

American Journal of Cardiovascular Drugs, Vol. 2, Iss. 4, 2002-01 ,pp. : 267-274

Adis International

Access to resources Recommend Favorite

The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

By Voors Adriaan A  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 8, 2013-08 ,pp. : 1041-1047

Informa Healthcare

Access to resources Recommend Favorite

Demographics, Treatment Regimens and the Use of Angiotensin-receptor Blockers in Heart Failure: Findings from the Valsartan Heart Failure Trial

By Majahalme S  

The Journal of International Medical Research, Vol. 31, Iss. 5, 2003-09 ,pp. : 351-361

Field House Publishing

Access to resources Recommend Favorite

Valsartan improves quality of life for patients with heart failure

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 363, 2002-01 ,pp. : 3-4

Adis International

Access to resources Recommend Favorite

Valsartan reduces risk of atrial fibrillation in heart failure

By  

Inpharma, Vol. 1, Iss. 1488, 2005-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite